New chemotherapy for patients with advanced hepatocellular carcinoma: Pilot study of β-interferon and doxorubicin one-shot intra-arterial chemotherapy

Hepatology Research

Volumn 37, Issue 12, 2007, Pages 1018-1025

  Uyama, Hirokazu ^a   Nagano, Hiroaki ^a   Nakamura, Hideji ^b   Murakami, Takamichi ^a   Nakamura, Hironobu ^a   Monden, Morito ^a   Hayashi, Norio ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b HYOGO COLLEGE OF MEDICINE   (Japan)

Author keywords

interferon; Advanced hepatocellular carcinoma; Doxorubicin; Intra arterial injection

Indexed keywords

BETA INTERFERON; BILIRUBIN; DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; ADVANCED CANCER; AGED; ARTICLE; ARTIFICIAL EMBOLISM; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DEATH; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HUMAN; LIVER CELL CARCINOMA; LIVER FAILURE; LIVER FUNCTION; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PILOT STUDY; PRIORITY JOURNAL; PROGNOSIS; RADIOFREQUENCY ABLATION; SEPSIS; STOMATITIS; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 35648959712     PISSN: 13866346     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2007.00158.x     Document Type: Article

References (23)

1. McGlynn KA, London WT. Epidemiology and natural history of hepatocellular carcinoma. Best Pract Res Clin Gastroenterol 2005; 19: 3-23.
2. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999; 340: 745-50.
3. Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: Incidence and risk factors. Gastroenterology 2004; 127: S35-50.
4. Tateishi R, Shiina S, Teratani T et al. Percutaneous radiofrequency ablation for hepatocellular carcinoma. An analysis of 1000 cases. Cancer 2005; 103: 1201-9.
5. Fujii T, Takayasu K, Muramatsu Y et al. Hepatocellular carcinoma with portal tumor thrombus: Analysis of factors determining prognosis. Jpn J Clin Oncol 1993; 23: 105-9.
6. Sakon M, Nagano H, Dono K et al. Combined intraarterial 5-fluorouracil and subcutaneous interferon-α therapy for advanced hepatocellular carcinoma with tumor thrombi in the major portal branches. Cancer 2002; 94: 435-42.
7. Ota H, Nagano H, Sakon M et al. Treatment of hepatocellular carcinoma with major portal vein thrombosis by combined therapy with subcutaneous interferon-alpha and intra-arterial 5-fluorouracil; role of type 1 interferon receptor expression. Br J Cancer 2005; 93: 557.
8. Llovet JM, Brù C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC-staging classification. Semin Liver Dis 1999; 19: 329-38.
9. Perez R, Pravia R, Artimez ML et al. Clinical efficacy of intramuscular human interferon-beta vs interferon-alpha 2b for the treatment of chronic hepatitis C. J Viral Hepat 1995; 2: 103-6.
10. Obora A, Shiratori Y, Okuno M et al. Synergistic induction of apoptosis by acyclic retinoid and interferon-beta in human hepatocellular carcinoma cells. Hepatology 2002; 36: 1115-24.
11. Damdinsuren B, Nagano H, Sakon M et al. Interferon-beta is more potent than interferon-alpha in inhibition of human hepatocellular carcinoma cell growth when used alone and in combination with anticancer drugs. Ann Surg Oncol 2003; 10: 1184-90.
12. Von Hoff DD, Layard MW, Basa P et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979; 91: 710-17.
13. Benjamin RS, Riggs CE Jr, Bachur NR. Plasma pharmacokinetics of adriamycin and its metabolites in humans with normal hepatic and renal function. Cancer Res 1977; 37: 1416-20.
14. Trotti A, Colevas AD, Setser A et al. CTCAE v3.0: Development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 2003; 13: 176-81.
15. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92: 205-16.
16. Varotti G, Ramacciato G, Ercolani G et al. Comparison between the fifth and sixth editions of the AJCC/UICC TNM staging systems for hepatocellular carcinoma: Multicentric study on 393 cirrhotic resected patients. Eur J Surg Oncol 2005; 31: 760-7.
17. A new prognostic system for hepatocellular carcinoma: A retrospective study of 435 patients: The Cancer of the Liver Italian Program (CLIP) investigators. Hepatology 1998; 28: 751-5.
18. Eksborg S, Cedermark BJ, Strandler HS. Intrahepatic and intravenous administration of adriamycin -a comparative pharmacokinetic study in patients with malignant liver tumours. Med Oncol Tumor Pharmacother 1985; 2: 47-54.
19. Doherty MM, Pang KS. First-pass effect: Significance of the intestine for absorption and metabolism. Drug Chem Toxicol 1997; 20: 329-44.
20. Di Marco A, Gaetani M, Scarpinato B. Adriamycin (NSC-123,127): A new antibiotic with antitumor activity. Cancer Chemother Rep 1969; 53: 33-7.
21. Muriel P. Alpha-interferon prevents liver collagen deposition and damage induced by prolonged bile duct obstruction in the rat. J Hepatol 1996; 24: 614-21.
22. Yang TS, Wang CH, Hsieh RK, Chen JS, Fung MC. Gemcitabine and doxorubicin for the treatment of patients with advanced hepatocellular carcinoma: A phase I-II trial. Ann Oncol 2002; 13: 1771-8.
23. Obi S, Yoshida H, Toune R et al. Combination therapy of intraarterial 5-fluorouracil and systemic interferon-alpha for advanced hepatocellular carcinoma with portal venous invasion. Cancer 2006; 106: 1990-7.